Journal article
Aspergillus and progression of lung disease in children with cystic fibrosis
Sabariah Noor Harun, Claire E Wainwright, Keith Grimwood, Stefanie Hennig, Joyce Cheney, Narelle George, Colin F Robertson, Rosemary Carzino, Marj Moodie, David S Armstrong, Peter J Cooper, A James Martin, Bruce Whitehead, Catherine A Byrnes, Harm A Tiddens, Nicholas Gailer, Katrina Jess, Peta Yarrow, Merilyn McArthur, Sam Forbes Show all
THORAX | BMJ PUBLISHING GROUP | Published : 2019
Abstract
BACKGROUND: The impact of Aspergillus on lung disease in young children with cystic fibrosis is uncertain. AIMS: To determine if positive respiratory cultures of Aspergillus species are associated with: (1) increased structural lung injury at age 5 years; (2) accelerated lung function decline between ages 5 years and 14 years and (3) to identify explanatory variables. METHODS: A cross-sectional analysis of association between Aspergillus positive bronchoalveolar lavage (BAL) cultures and chest high-resolution CT (HRCT) scan findings at age 5 years in subjects from the Australasian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) study was performed. A non-linear mixed-effects disease progress..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The original AC FBAL study was supported by the National Health and Medical Research Council (grants 9937868 and 351541) and the Children's Hospital Foundation Queensland, Australia. The tobramycin inhalation solution and delivery system used throughout the AC FBAL study was supplied by Pathogenesis Corporation, Chiron Corporation and Novartis Pharmaceuticals Inc.